Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels

Pharmacology, Toxicology and Pharmaceutical Science

• Transforming Growth Factor 100%
• Fibrinogen 90%
• Protein 40%
• Creatinine 40%
• Losartan 40%
• Dipeptidyl Carboxypeptidase Inhibitor 30%
• Kidney Failure 20%
• Population Study 20%
• Receptor 10%
• Angiotensin II 10%
• Deterioration 10%
• Dipeptidyl Carboxypeptidase 10%
• Kidney Disease 10%
• Diabetic Nephropathy 10%
• Angiotensin Receptor 10%
• Angiotensin 1 Receptor Antagonist 10%
• Add on Therapy 10%
• Enzyme Inhibition 10%
• Chronic Glomerulonephritis 10%
• Placebo 10%
• Randomized Controlled Trial 10%
• Lisinopril 10%

Neuroscience

• Transforming Growth Factor 100%
• Fibrinogen 90%
• Dipeptidyl Carboxypeptidase 40%
• Creatinine 40%
• Losartan 40%
• Enzyme Inhibitor 30%
• Eicosanoid Receptor 20%
• Angiotensin II 10%
• Randomized Controlled Trial 10%
• Body Mass Index 10%
• Angiotensin Receptor 10%
• Protein 10%
• Placebo 10%
• Enzyme Inhibition 10%
• Lisinopril 10%

Biochemistry, Genetics and Molecular Biology

• Transforming Growth Factor 100%
• Angiotensin-Converting Enzyme 40%
• Creatinine 40%
• Blood Pressure 40%
• Excretion 30%
• Protein Urine Level 30%
• Enzyme Inhibitor 30%
• Population Research 20%
• Reduction (Chemistry) 20%
• Body Mass 10%
• Systolic Blood Pressure 10%
• Receptor Blocking 10%
• Urine Level 10%
• Age 10%
• Enzyme Inhibition 10%